首页> 中文期刊> 《中华医学杂志(英文版)》 >Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer

Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer

         

摘要

Background:Altered immunoresponse is associated with tumorigenesis and cancer progression.This study assessed the levels of tumor-infiltrating CD3+ or CD8+ T lymphocytes and interleukin-2 (IL-2) protein in radically resected non-small cell lung cancer (NSCLC) tissues to predict overall survival (OS) of the patients.Methods:Paraffin-embedded tissue specimens from 129 NSCLC patients were retrospectively collected for immunostaining of CD8+,CD3+,and IL-2 expression.Clinicopathological and survival data were collected and analyzed using the Chi-squared test,Kaplan-Meier curves,and the log-rank test or the Cox regression model.Results:The data showed a significant inverse association between CD8+ T lymphocyte levels and IL-2 expression (r =-0.927; P =0.000) and between the levels ofCD8+ and CD3+ T lymphocytes (r =-0.722; P =0.000),but a positive association between CD3+ T lymphocyte levels and IL-2 expression (r =0.781; P =0.000) in NSCLC tissues.Furthermore,the levels ofCD3+ and CD8+ T lymphocytes and IL-2 expression were associated with tumor stage (P =0.023,0.006,and 0.031,respectively) and the level ofCD8+ T lymphocytes was associated with the patient gender (P =0.024).In addition,the levels ofCD8+ T lymphocytes were associated with an unfavorable 5-year OS,whereas patients with high levels ofCD3+ T lymphocytes in tumor lesions and IL-2-expressing tumors had significantly better 5-year OS rates than patients with low levels.Conclusions:The levels ofCD8+ T cells in tumor lesions and IL-2 expression were both independent predictors of OS for these NSCLC patients.Thus,the detection of tumor-infiltrating CD3+ or CD8+ T lymphocytes and IL-2 expression could be useful to predict the prognosis of radically resected NSCLC patients.

著录项

  • 来源
    《中华医学杂志(英文版)》 |2015年第1期|105-110|共6页
  • 作者单位

    Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China;

    2Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China;

    Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Oncology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China;

    Department of Oncology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China;

    Department of Oncology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号